



atecTM

INFORMED BY EOS

Q2 2025 FINANCIAL RESULTS

PAT MILES, CHAIRMAN & CEO | TODD KONING, CFO | JULY 31, 2025

FORWARD-LOOKING STATEMENTS

This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The Company cautions investors that there can be no assurance that actual results will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors. Forward-looking statements include, but are not limited to: references to the Company's revenue, balance sheet, growth, adjusted EBITDA, profitability, free cash flow, financial outlook and commitments; planned product launches, timelines, introductions, regulatory submissions or clearances; expansion of international markets; increases in U.S. market share and procedural volume, the ability to drive surgeon adoption, gain hospital access and create clinical distinction; the development and monetization of informatics platforms; the ability to transform the sales channel; and the Company's ability to finance its operations and sufficiency of its cash runway. Important factors that could cause actual operating results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to: the uncertainty of success in developing and commercializing new products or products currently in the pipeline; the uncertainties in the Company's ability to execute upon its strategic operating and long-range plan; the uncertainties regarding the ability to successfully license or acquire new products, and the commercial success of such products; failure to achieve acceptance of the Company's products by the surgeon community; failure to obtain FDA or other regulatory clearance or approval or unexpected or prolonged delays in the process; continuation of favorable third-party reimbursement; unanticipated expenses or liabilities or other adverse events affecting cash flow or the Company's ability to achieve profitability; uncertainty of additional funding; product liability exposure; an unsuccessful outcome in any litigation; patent infringement claims; claims related to the Company's intellectual property; competitive pressures and market dynamics; and the Company's ability to meet its financial obligations and achieve expected financial outcomes. A further list and description of these and other factors, risks and uncertainties can be found in the Company's most recent annual report, and any subsequent quarterly and current reports, filed with the U.S. Securities and Exchange Commission. ATEC disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.

Q2 2025 FINANCIAL HIGHLIGHTS

GROWTH LEADERSHIP

29%

Surgical revenue growth;
~6X market growth¹

ADJUSTED EBITDA

\$23M

Record 13% of revenue;
improving 880 bps YoY²

FREE CASH FLOW

+\$5M

Inflecting to positive cash
flow for full year

PROFITABLE, REVENUE-GROWTH LEADERSHIP

PROFITABLE GROWTH

Q2 2025 HIGHLIGHTS

\$186M

Total Revenue

27%

Total revenue
growth

29%

Surgical revenue
growth

29%

Revenue growth in
established territories

21%

Surgeon user
growth

\$23M

Adjusted
EBITDA

+\$5M

Free Cash Flow

\$217M

Cash and Access to Cash

PROFITABLE

Non-GAAP Net Income

3rd

In U.S. Market Share¹

Q2 2025 NON-GAAP P&L HIGHLIGHTS

DISCIPLINED EXECUTION DRIVING PROFITABILITY

	Q2 2025	YOY
Surgical Revenue	\$168M	29%
EOS Revenue	\$17M	11%
TOTAL REVENUE	\$186M	27%
Gross margin %	70%	(130) Bps
Total Operating Expense	66%	(1,260) bps
OPERATING MARGIN %	4%	1,130 bps
NON-GAAP NET INCOME	\$3M	

\$40M

Total revenue
YoY \$ growth

\$3M

Non-GAAP
Net Income

- 28% Surgical volume growth & 1% average revenue per case growth
- SG&A improvements driven by infrastructure leverage & lower variable costs
- Overall operating expenses grew 7% YoY
- Inflection to non-GAAP Net Income profitability

Q2 2025 NON-GAAP AEBITDA

DROP THROUGH ON REVENUE GROWTH OF 45% YOY

	Q2 2025	YOY
Adjusted EBITDA	\$23M	+\$18M
% OF SALES	13%	+880 bps

Adj. EBITDA leverage being driven by the areas we outlined and expected:

- Durable top-line growth
- Variable rate improvement
- Infrastructure leverage




BALANCE SHEET

INFLECTED TO POSITIVE CASH FLOW

BALANCE SHEET	Q2 2025
Cash	\$157M
Available Borrowing ¹	\$60M
CASH + AVAILABLE CASH	\$217M

CASH FLOW	
FREE CASH FLOW²	\$5M



Trailing 12-month free cash use reduced to (\$22M)

On track to achieve positive FCF in 2025

| 1. The Company had \$60M of undrawn credit available on its Midcap revolving line of credit at period end | 2. Free cash flow defined as cash generated by operating activities less PP&E

ROBUST OUTLOOK FOR 2025

CONTINUED CLINICAL DISTINCTION-DRIVEN REVENUE & PROFIT GROWTH

\$742M

Total revenue

\$83M

Adjusted EBITDA

Positive

Free cash flow


2025 AEBITDA OUTLOOK

DRIVING POWERFUL LEVERAGE BY DESIGN

\$83M

Adjusted EBITDA

40% drop through of YoY \$ revenue growth to \$ AEBITDA



| Reference historical non-GAAP reconciliation in appendix

OUR STRATEGY IS STEADFAST. OUR EXECUTION IS RELENTLESS.

EXECUTING WITH PRECISION AND MOMENTUM—FULFILLING COMMITMENTS

1

CREATE CLINICAL DISTINCTION

Architect unparalleled
procedural solutions
that improve patient
outcomes

2

COMPEL SURGEON ADOPTION

Earn loyalty through
differentiated training,
technology, and clinical value

3

EXPAND, ELEVATE & ENABLE SALES FORCE

Build a high-performing,
aligned sales force designed
to scale and win

THE SPINE MARKET NEEDS ATEC

SPINE IS UNSETTLED—REVISION RATES ARE UNACCEPTABLY HIGH

SPINE'S MOST PERVASIVE CHALLENGE:
LACK OF DURABILITY

% OF SURGERIES THAT
REQUIRE REVISION¹

3%




TOTAL KNEE
5 years

>5%




TOTAL HIP
REPLACEMENT
10 years

10-15%





DEGENERATIVE
SURGERY
1 to 3 years

25-30%




ADULT DEFORMITY
SURGERY
2 to 5 years

HISTORICAL INDUSTRY
INVESTMENT THESIS FOCUSED ON
FLAWED CURRENCY



ECOSYSTEM BUILT FOR LONG RUN

EARLY INFORMATICS INVESTMENTS FUELING DURABLE LONG-TERM GROWTH AND PROFITABILITY



DATA-DRIVEN ECOSYSTEM, INFORMING EVERY PROCEDURE

**THE MOST COVETED ECOSYSTEM.
THE BEST INTEGRATED EXPERIENCE.**

EOS
Insight





VALENCETM
ROBOTIC NAVIGATION SYSTEM

SAFEOP
SURGICAL INFORMATIX SYSTEM

OBJECTIVE MEASURE ENABLES VARIABLE MITIGATION

AUTOMATION OTHERS CAN'T REPLICATE



THE SPINE MARKET NEEDS ATEC

COMMITTED TO CLINICAL DISTINCTION

ATEC: SOLVING SPINE'S MOST PERVASIVE CHALLENGE,
ONE VARIABLE AT A TIME

% OF SURGERIES THAT
REQUIRE REVISION¹

3%




TOTAL KNEE
5 years

>5%




TOTAL HIP
REPLACEMENT
10 years

10-15%



DEGENERATIVE
SURGERY
1 to 3 years

25-30%



ADULT DEFORMITY
SURGERY
2 to 5 years

EARNING SHARE IN A DISRUPTED &
DISTRACTED MARKET THROUGH
100% SPINE FOCUS

3RD
IN U.S.
MARKET
SHARE²



GLOBUS
MEDICAL



VISCOGLIOSI BROTHERS, LLC

atec[™]
INFORMED BY EOS



**THE PREFERRED
DESTINATION.**

**100% SPINE FOCUS
UNMATCHED CLINICAL KNOW-HOW
SALES FORCE INVESTMENT**



**WE'RE JUST
GETTING STARTED.
OUR BEST
IS YET TO COME.**





atecTM

INFORMED BY EOS

APPENDIX

SUPPLEMENTAL FINANCIAL INFORMATION



HISTORICAL GAAP P&L TREND - CONSOLIDATED (\$'000's)

	Q123	Q223	Q323	Q423	2023	Q124	Q224	Q324	Q424	2024	Q125	Q225
Revenue from products and services	\$ 109,110	\$ 116,920	\$ 118,262	\$ 137,970	\$ 482,262	\$ 138,477	\$ 145,573	\$ 150,719	\$ 176,793	\$ 611,562	\$ 169,180	\$ 185,544
Cost of sales	38,685	52,379	38,215	42,780	172,059	41,126	42,979	47,990	55,205	187,300	53,184	56,443
Gross profit	70,425	64,541	80,047	95,190	310,203	97,351	102,594	102,729	121,588	424,262	115,996	129,101
Operating expenses:												
Research and development	13,260	14,571	20,000	22,284	70,115	18,012	19,105	20,357	23,244	80,718	17,032	18,276
Sales, general and administrative	91,262	87,287	91,411	104,120	374,080	113,727	112,731	109,200	114,541	450,199	127,017	118,507
Litigation-related expenses	3,192	6,908	2,715	9,472	22,287	4,428	2,090	2,093	1,188	9,799	12,214	1,593
Amortization of acquired intangibles	2,883	3,705	3,873	3,823	14,284	3,854	3,836	3,848	4,720	16,258	3,653	3,803
Transaction-related expenses	-	1,900	278	(65)	2,113	(117)	-	-	327	210	-	-
Restructuring expenses	175	29	129	386	719	788	139	934	1,386	3,247	371	7
Gain on Settlement	-	-	-	-	-	-	-	-	-	-	-	-
Total operating expenses	110,772	114,400	118,406	140,020	483,598	140,692	137,901	136,432	145,406	560,431	160,287	142,186
Operating Loss	(40,347)	(49,859)	(38,359)	(44,830)	(173,395)	(43,341)	(35,307)	(33,703)	(23,818)	(136,169)	(44,291)	(13,085)
Other expense, net:												
Cash interest expense, net	(3,014)	(3,038)	(3,581)	(3,367)	(13,000)	(4,283)	(4,754)	(5,417)	(5,967)	(20,421)	(5,356)	(5,289)
Noncash interest expense, net	(860)	(854)	(878)	(1,049)	(3,641)	(1,058)	(1,061)	(1,155)	(1,184)	(4,458)	(2,485)	(7,020)
Loss on debt extinguishment	-	-	-	-	-	-	-	-	-	-	(17,576)	-
Gain on derivative liability	-	-	-	-	-	-	-	-	-	-	17,400	(16,780)
Other (expense) income, net	706	2,324	47	44	3,121	118	156	623	(1,922)	(1,025)	337	993
Total other expense, net	(3,168)	(1,568)	(4,412)	(4,372)	(13,520)	(5,223)	(5,659)	(5,949)	(9,073)	(25,904)	(7,680)	(28,096)
Net loss before taxes	(43,515)	(51,427)	(42,771)	(49,202)	(186,915)	(48,564)	(40,966)	(39,652)	(32,891)	(162,073)	(51,971)	(41,181)
Income tax provision (benefit)	14	(50)	(117)	(124)	(277)	(69)	(286)	(36)	441	50	(64)	(37)
Net loss, GAAP	\$ (43,529)	\$ (51,377)	\$ (42,654)	\$ (49,078)	\$ (186,638)	\$ (48,495)	\$ (40,680)	\$ (39,616)	\$ (33,332)	\$ (162,123)	\$ (51,907)	\$ (41,144)
Net loss per share, GAAP	\$ (0.40)	\$ (0.43)	\$ (0.35)	\$ (0.37)	\$ (1.54)	\$ (0.34)	\$ (0.29)	\$ (0.28)	\$ (0.23)	\$ (1.13)	\$ (0.35)	\$ (0.27)
Weighted average shares outstanding, basic and diluted	109,751	118,719	122,468	133,750	121,242	140,980	142,687	143,492	144,583	142,946	146,732	149,907

SUPPLEMENTAL FINANCIAL INFORMATION



HISTORICAL GAAP P&L TREND - CONSOLIDATED (\$'000's)

	Q123	Q223	Q323	Q423	2023	Q124	Q224	Q324	Q424	2024	Q125	Q225
Revenue from products and services	\$ 109,110	\$ 116,920	\$ 118,262	\$ 137,970	\$ 482,262	\$ 138,477	\$ 145,573	\$ 150,719	\$ 176,793	\$ 611,562	\$ 169,180	\$ 185,544
Cost of sales	38,685	52,379	38,215	42,780	172,059	41,126	42,979	47,990	55,205	187,300	53,184	56,443
Gross profit	70,425	64,541	80,047	95,190	310,203	97,351	102,594	102,729	121,588	424,262	115,996	129,101
Operating expenses:												
Research and development	13,260	14,571	20,000	22,284	70,115	18,012	19,105	20,357	23,244	80,718	17,032	18,276
Sales, general and administrative	91,262	87,287	91,411	104,120	374,080	113,727	112,731	109,200	114,541	450,199	127,017	118,507
Litigation-related expenses	3,192	6,908	2,715	9,472	22,287	4,428	2,090	2,093	1,188	9,799	12,214	1,593
Amortization of acquired intangibles	2,883	3,705	3,873	3,823	14,284	3,854	3,836	3,848	4,720	16,258	3,653	3,803
Transaction-related expenses	-	1,900	278	(65)	2,113	(117)	-	-	327	210	-	-
Restructuring expenses	175	29	129	386	719	788	139	934	1,386	3,247	371	7
Gain on Settlement	-	-	-	-	-	-	-	-	-	-	-	-
Total operating expenses	110,772	114,400	118,406	140,020	483,598	140,692	137,901	136,432	145,406	560,431	160,287	142,186
Operating Loss	(40,347)	(49,859)	(38,359)	(44,830)	(173,395)	(43,341)	(35,307)	(33,703)	(23,818)	(136,169)	(44,291)	(13,085)
Other expense, net:												
Cash interest expense, net	(3,014)	(3,038)	(3,581)	(3,367)	(13,000)	(4,283)	(4,754)	(5,417)	(5,967)	(20,421)	(5,356)	(5,289)
Noncash interest expense, net	(860)	(854)	(878)	(1,049)	(3,641)	(1,058)	(1,061)	(1,155)	(1,184)	(4,458)	(2,485)	(7,020)
Loss on debt extinguishment	-	-	-	-	-	-	-	-	-	-	(17,576)	-
Gain on derivative liability	-	-	-	-	-	-	-	-	-	-	17,400	(16,780)
Other (expense) income, net	706	2,324	47	44	3,121	118	156	623	(1,922)	(1,025)	337	993
Total other expense, net	(3,168)	(1,568)	(4,412)	(4,372)	(13,520)	(5,223)	(5,659)	(5,949)	(9,073)	(25,904)	(7,680)	(28,096)
Net loss before taxes	(43,515)	(51,427)	(42,771)	(49,202)	(186,915)	(48,564)	(40,966)	(39,652)	(32,891)	(162,073)	(51,971)	(41,181)
Income tax provision (benefit)	14	(50)	(117)	(124)	(277)	(69)	(286)	(36)	441	50	(64)	(37)
Net loss, GAAP	\$ (43,529)	\$ (51,377)	\$ (42,654)	\$ (49,078)	\$ (186,638)	\$ (48,495)	\$ (40,680)	\$ (39,616)	\$ (33,332)	\$ (162,123)	\$ (51,907)	\$ (41,144)
Net loss per share, GAAP	\$ (0.40)	\$ (0.43)	\$ (0.35)	\$ (0.37)	\$ (1.54)	\$ (0.34)	\$ (0.29)	\$ (0.28)	\$ (0.23)	\$ (1.13)	\$ (0.35)	\$ (0.27)
Weighted average shares outstanding, basic and diluted	109,751	118,719	122,468	133,750	121,242	140,980	142,687	143,492	144,583	142,946	146,732	149,907

SUPPLEMENTAL FINANCIAL INFORMATION



NON-GAAP RECONCILIATION - CONSOLIDATED (\$000's)

ADJUSTED EBITDA	Q123	Q223	Q323	Q423	2023	Q124	Q224	Q324	Q424	2024	Q125	Q225
Net loss, GAAP	\$ (43,529)	\$ (51,377)	\$ (42,654)	\$ (49,078)	\$ (186,638)	\$ (48,495)	\$ (40,680)	\$ (39,616)	\$ (33,332)	\$ (162,123)	\$ (51,907)	\$ (41,144)
Cash interest expense, net	3,014	3,038	3,581	3,367	13,000	4,283	4,754	5,417	5,967	20,421	5,356	5,289
Noncash interest expense, net	860	854	878	1,049	3,641	1,058	1,061	1,155	1,184	4,458	2,485	7,020
Loss on debt extinguishment	-	-	-	-	-	-	-	-	-	-	17,576	-
Gain on derivative liability	-	-	-	-	-	-	-	-	-	-	(17,400)	16,780
Other (expense) income, net	(706)	(2,324)	(47)	(44)	(3,121)	(118)	(156)	(623)	1,922	1,025	(337)	(993)
Income tax provision (benefit)	14	(50)	(117)	(124)	(277)	(69)	(286)	(36)	441	50	(64)	(37)
Depreciation expense	8,589	9,758	10,651	11,918	40,916	13,724	15,735	16,491	16,102	62,052	15,754	15,012
Amortization expense	3,103	3,925	4,094	4,101	15,223	4,161	4,143	4,156	3,906	16,366	4,153	4,316
Total EBITDA	(28,655)	(36,176)	(23,614)	(28,811)	(117,256)	(25,456)	(15,429)	(13,056)	(3,810)	(57,751)	(24,384)	6,243
+ Stock-based compensation	16,462	24,194	20,073	20,515	81,244	17,322	16,960	17,462	21,533	73,277	22,318	15,624
+ Purchase accounting adjustments on acquisitions	195	-	-	198	393	-	197	-	-	197	-	-
+ Litigation-related expenses	3,192	6,908	2,715	9,472	22,287	4,428	2,090	2,093	1,188	9,799	12,214	1,593
+ Transaction-related expenses	-	1,900	278	(65)	2,113	(117)	-	-	327	210	-	-
+ Restructuring expenses	175	29	129	386	719	788	139	934	1,386	3,247	371	7
+ Other non-recurring expenses	1,349	-	-	-	1,349	-	1,608	-	-	1,608	-	-
Total Adjusted EBITDA	\$ (7,282)	\$ (3,145)	\$ (419)	\$ 1,695	\$ (9,151)	\$ (3,035)	\$ 5,565	\$ 7,433	\$ 20,624	\$ 30,587	\$ 10,519	\$ 23,467
Adjusted EBITDA as a % of Revenue	-6.7%	-2.7%	-0.4%	1.2%	-1.9%	-2.2%	3.8%	4.9%	11.7%	5.0%	6.2%	12.6%
NON-GAAP EARNINGS (LOSS) PER SHARE	Q123	Q223	Q323	Q423	2023	Q124	Q224	Q324	Q424	2024	Q125	Q225
Net Loss, GAAP	\$ (43,529)	\$ (51,377)	\$ (42,654)	\$ (49,078)	\$ (186,638)	\$ (48,495)	\$ (40,680)	\$ (39,616)	\$ (33,332)	\$ (162,123)	\$ (51,907)	\$ (41,144)
+ Stock-based compensation	16,462	24,194	20,073	20,515	81,244	17,322	16,960	17,462	21,533	73,277	22,318	15,624
+ Amortization of acquired intangible assets	3,103	3,925	4,094	4,101	15,223	4,161	4,143	4,156	3,906	16,366	3,703	3,867
+ Restructuring expenses	175	29	129	386	719	788	139	934	1,386	3,247	371	7
+ Transaction-related expenses	-	1,900	278	(65)	2,113	(117)	-	-	327	210	-	-
+ Litigation-related expenses	3,192	6,908	2,715	9,472	22,287	4,428	2,090	2,093	1,188	9,799	12,214	1,593
+ Loss on Debt extinguishment	-	-	-	-	-	-	-	-	-	-	17,576	-
+ Gain on derivative liability	-	-	-	-	-	-	-	-	-	-	(17,400)	16,780
+ Noncash interest expense, net	860	854	878	1,049	3,641	1,058	1,061	1,155	1,184	4,458	2,485	7,020
+ Foreign exchange impact	(209)	265	7	16	79	(119)	(44)	(624)	1,592	805	(311)	(308)
+ Long-term income tax rate adjustment	5,168	3,522	3,912	3,693	16,295	5,448	4,606	3,800	21	13,875	2,928	(848)
Non-GAAP net income (loss)	\$ (14,778)	\$ (9,780)	\$ (10,568)	\$ (9,911)	\$ (45,037)	\$ (15,526)	\$ (11,725)	\$ (10,640)	\$ (2,195)	\$ (40,086)	\$ (8,023)	\$ 2,591
Non-GAAP net income (loss) per share	\$ (0.13)	\$ (0.08)	\$ (0.09)	\$ (0.07)	\$ (0.37)	\$ (0.11)	\$ (0.08)	\$ (0.07)	\$ (0.02)	\$ (0.28)	\$ (0.05)	\$ 0.02
Weighted avg shares outstanding, basic and diluted	109,751	118,719	122,468	133,750	121,242	140,980	142,687	143,492	144,583	142,946	146,732	149,907


SUPPLEMENTAL FINANCIAL INFORMATION



NON-GAAP P&L TREND - CONSOLIDATED (\$000's)

	Q123	Q223	Q323	Q423	2023	Q124	Q224	Q324	Q424	2024	Q125	Q225
Revenue from products and services	\$ 109,110	\$ 116,920	\$ 118,262	\$ 137,970	\$ 482,262	\$ 138,477	\$ 145,573	\$ 150,719	\$ 176,793	\$ 611,562	\$ 169,180	\$ 185,544
Non-GAAP cost of sales	32,264	35,933	35,625	41,823	145,645	40,336	41,921	46,243	53,534	182,034	50,091	55,826
Non-GAAP gross profit	\$ 76,846	\$ 80,987	\$ 82,637	\$ 96,147	\$ 336,617	\$ 98,141	\$ 103,652	\$ 104,476	\$ 123,259	\$ 429,528	\$ 119,089	\$ 129,718
<i>Non-GAAP Gross Margin</i>	70.4%	69.3%	69.9%	69.7%	69.8%	70.9%	71.2%	69.3%	69.7%	70.2%	70.4%	69.9%
Non-GAAP Operating expenses:												
Non-GAAP research & development	11,943	13,091	13,210	13,130	51,374	13,697	13,491	13,150	13,350	53,688	13,388	14,117
Non-GAAP sales, general & administrative	80,774	80,799	80,497	93,240	335,310	101,203	100,331	100,384	105,387	407,305	111,386	107,595
Total non-GAAP operating expenses	\$ 92,717	\$ 93,890	\$ 93,707	\$ 106,370	\$ 386,684	\$ 114,900	\$ 113,822	\$ 113,534	\$ 118,737	\$ 460,993	\$ 124,774	\$ 121,712
<i>Non-GAAP R&D as % of revenue</i>	10.9%	11.2%	11.2%	9.5%	10.7%	9.9%	9.3%	8.7%	7.6%	8.8%	7.9%	7.6%
<i>Non-GAAP SG&A as % of revenue</i>	74.0%	69.1%	68.1%	67.6%	69.5%	73.1%	68.9%	66.6%	59.6%	66.6%	65.8%	58.0%
<i>Total Non-GAAP OPEX as % of revenue</i>	84.9%	80.3%	79.2%	77.1%	80.2%	83.0%	78.2%	75.3%	67.2%	75.4%	73.8%	65.6%
Non-GAAP operating loss	(15,871)	(12,903)	(11,070)	(10,223)	(50,067)	(16,759)	(10,170)	(9,058)	4,522	(31,465)	(5,685)	8,006
<i>Op loss as % of revenue</i>	-14.5%	-11.0%	-9.4%	-7.4%	-10.4%	-12.1%	-7.0%	-6.0%	2.6%	-5.1%	-3.4%	4.3%
Less: Other amortization expense	-	-	-	-	-	-	-	-	-	-	450	449
Less: Depreciation expense	8,589	9,758	10,651	11,918	40,916	13,724	15,735	16,491	16,102	62,052	15,754	15,012
Adjusted EBITDA	\$ (7,282)	\$ (3,145)	\$ (419)	\$ 1,695	\$ (9,151)	\$ (3,035)	\$ 5,565	\$ 7,433	\$ 20,624	\$ 30,587	\$ 10,519	\$ 23,467
<i>Adj EBITDA as % of revenue</i>	-6.7%	-2.7%	-0.4%	1.2%	-1.9%	-2.2%	3.8%	4.9%	11.7%	5.0%	6.2%	12.6%
<i>Adj EBITDA drop through %</i>	14.2%	22.9%	30.5%	22.8%	22.0%	14.5%	30.4%	24.2%	48.8%	30.7%	44.1%	44.8%

SUPPLEMENTAL FINANCIAL INFORMATION

 REVENUE SUPPLEMENT												
	Q123	Q223	Q323	Q423	2023	Q124	Q224	Q324	Q424	2024	Q125	Q225
Revenues:												
Products and services - Surgical	94,040	102,306	103,823	122,594	422,763	122,617	130,028	135,343	156,468	544,456	152,084	168,217
Products and services - EOS	15,070	14,614	14,439	15,376	59,499	15,860	15,545	15,376	20,325	67,106	17,096	17,327
Total revenue from products and services	\$ 109,110	\$ 116,920	\$ 118,262	\$ 137,970	\$ 482,262	\$ 138,477	\$ 145,573	\$ 150,719	\$ 176,793	\$ 611,562	\$ 169,180	\$ 185,544
Constant currency adjustments:												
Products and services - Surgical	17	(6)	4	42	57	15	22	(44)	(72)	(79)	180	80
Products and services - EOS	363	15	(319)	(266)	(207)	(88)	42	(39)	(146)	(231)	260	(167)
Revenue from products and services	380	9	(315)	(224)	(150)	(73)	64	(83)	(218)	(310)	440	(87)
TOTAL ADJUSTMENTS	380	9	(315)	(224)	(150)	(73)	64	(83)	(218)	(310)	440	(87)
Revenues at constant currency:												
Products and services - Surgical	94,087	102,300	103,827	122,636	422,820	122,632	130,050	135,299	156,396	544,377	152,264	168,297
Products and services - EOS	15,403	14,629	14,120	15,110	59,292	15,772	15,586	15,337	20,179	66,874	17,356	17,160
Total Revenue at Constant Currency	\$ 109,490	\$ 116,929	\$ 117,947	\$ 137,746	\$ 482,112	\$ 138,404	\$ 145,637	\$ 150,636	\$ 176,575	\$ 611,252	\$ 169,620	\$ 185,457
YOY GROWTH %												
Products and services - Surgical	55.1%	41.4%	31.9%	34.2%	39.5%	30.4%	27.1%	30.4%	27.6%	28.8%	24.0%	29.4%
Products and services - EOS	46.5%	23.8%	29.9%	5.2%	24.4%	5.2%	6.4%	6.5%	32.2%	12.8%	7.8%	11.5%
Total revenue from products and services	53.8%	38.9%	31.6%	30.2%	37.4%	26.9%	24.5%	27.4%	28.1%	26.8%	22.2%	27.5%
YOY growth % at constant currency:												
Products and services - Surgical	55.1%	41.4%	31.9%	34.3%	39.5%	30.3%	27.1%	30.3%	27.5%	28.7%	24.1%	29.4%
Products and services - EOS	45.9%	17.7%	19.1%	-3.4%	17.5%	2.4%	6.5%	8.6%	33.5%	12.8%	10.0%	10.1%
Total Revenue Growth % at Constant Currency	53.7%	37.9%	30.2%	28.8%	36.4%	26.4%	24.6%	27.7%	28.2%	26.8%	22.5%	27.3%